What is the diagnostic work‑up and initial management for an adult presenting with dyspnea, cough, wheeze and reduced exercise tolerance suggestive of obstructive airway disease (asthma versus chronic obstructive pulmonary disease)?

Diagnostic Work-Up and Initial Management of Suspected Obstructive Airway Disease

Perform post-bronchodilator spirometry immediately in any adult presenting with dyspnea, cough, wheeze, and reduced exercise tolerance; a post-bronchodilator FEV1/FVC <0.70 with minimal reversibility (<12% and <200 mL improvement) confirms COPD, while significant reversibility (≥12% and ≥200 mL) suggests asthma. 1, 2, 3

Initial Clinical Assessment

History Elements That Distinguish COPD from Asthma

Age and smoking history:

• COPD typically presents after age 40 with ≥20 pack-year smoking history or significant occupational/environmental exposures 1, 3, 4
• Asthma can begin at any age, often in childhood or adolescence, without necessary smoking exposure 2, 3, 4

Symptom pattern:

• COPD: Progressive, persistent breathlessness that worsens gradually over years, morning-predominant productive cough, symptoms do not vary markedly day-to-day 1, 3
• Asthma: Variable symptoms with symptom-free intervals, nocturnal or early-morning symptoms, triggered by allergens/exercise/cold air 2, 3, 4

Associated conditions:

• COPD: History of chronic bronchitis (sputum production ≥3 months for 2 consecutive years), weight loss and anorexia in severe disease 1, 3
• Asthma: Personal history of atopy, allergic rhinitis, eczema, or family history of asthma 2, 3, 4

Physical Examination Findings

COPD indicators:

• Lung hyperinflation, reduced breath sounds, wheezes, prolonged expiratory phase 1
• Cyanosis, peripheral edema, use of accessory muscles in severe disease 1

Note: Physical examination alone has low sensitivity for detecting moderate-to-severe COPD and cannot replace spirometry 3

Diagnostic Testing Algorithm

Step 1: Post-Bronchodilator Spirometry (Required for Diagnosis)

Perform spirometry before and 15-20 minutes after administering a short-acting bronchodilator (typically 400 mcg salbutamol). 1

Interpretation:

• COPD confirmed: Post-bronchodilator FEV1/FVC <0.70 with minimal reversibility (improvement <12% predicted and <200 mL) 1, 2, 3
• Asthma likely: Significant reversibility (≥12% and ≥200 mL improvement in FEV1) 1, 2
• Asthma-COPD Overlap (ACO): Post-bronchodilator FEV1/FVC <0.70 with significant reversibility (≥12% and ≥200 mL), typically in patients >40 years with smoking history but also features of asthma 2, 3, 5

Step 2: Additional Testing Based on Initial Spirometry

If spirometry shows obstruction (FEV1/FVC <0.70):

• Chest radiograph to exclude alternative diagnoses (bronchiectasis, lung cancer, cardiac failure) but cannot positively diagnose COPD 1
• Consider corticosteroid trial: 30 mg prednisolone daily for 2 weeks with repeat spirometry; objective improvement (≥10% predicted FEV1 and/or ≥200 mL) suggests asthma component 1, 3

If spirometry is normal but clinical suspicion for asthma remains high:

• Perform methacholine or histamine challenge test; PC20 <2 mg/mL confirms airway hyperresponsiveness and supports asthma diagnosis 2, 3
• Measure peak expiratory flow variability over 2 weeks; >15% variability suggests asthma 2, 3

For suspected COPD with emphysema:

• Measure diffusing capacity for carbon monoxide (DLCO); reduced DLCO supports emphysema and helps differentiate from asthma 3, 4

For patients <45 years or with atypical features:

• Alpha-1 antitrypsin level to exclude genetic deficiency 3

Initial Management Based on Diagnosis

For Confirmed COPD (Post-Bronchodilator FEV1/FVC <0.70, Minimal Reversibility)

Immediate interventions:

1. Smoking cessation counseling and pharmacotherapy (the only intervention proven to slow FEV1 decline and improve survival; continuing smokers lose ~70 mL FEV1/year vs. 20-30 mL/year in non-smokers) 3

2. Start long-acting bronchodilator monotherapy:

   • Long-acting muscarinic antagonist (LAMA) preferred over long-acting beta-agonist (LABA) for exacerbation prevention 2, 3
   • Examples: tiotropium 18 mcg daily, or umeclidinium 62.5 mcg daily 2

3. Escalation pathway if symptoms persist:

   • Add second long-acting bronchodilator (LABA + LAMA combination) for moderate-to-severe COPD 2, 3
   • Add inhaled corticosteroids (ICS) only if: frequent exacerbations (≥2/year) despite optimal bronchodilator therapy, blood eosinophilia, or features of asthma-COPD overlap 1, 2, 3

Critical pitfall: Do not routinely add ICS in COPD without specific indications; ICS increases pneumonia risk and does not slow FEV1 decline 2, 3

For Confirmed Asthma (Significant Reversibility or Positive Challenge Test)

Immediate interventions:

1. Start low-dose inhaled corticosteroids (ICS) as controller medication (first-line therapy for persistent asthma) 2, 3

   • Examples: beclomethasone 200-400 mcg/day or equivalent 2

2. Prescribe short-acting beta-agonist (SABA) for symptom relief (e.g., salbutamol 100-200 mcg as needed) 3

3. Escalation pathway if symptoms persist:

   • Add LABA to low-to-medium dose ICS for moderate persistent asthma 2, 3
   • Increase to high-dose ICS/LABA combination for severe persistent asthma 2, 3
   • Consider add-on therapies (leukotriene modifiers, tiotropium) for difficult-to-control asthma 3

For Asthma-COPD Overlap (ACO)

ACO is present when all of the following are met: age ≥40 years, current/former smoking, post-bronchodilator FEV1/FVC <0.70, and ≥12% and ≥200 mL reversibility 2, 3, 5

Initial management:

1. Start ICS/LABA combination therapy as first-line treatment (ICS must be part of the regimen in all ACO patients) 2, 3

2. Add LAMA if symptoms persist (triple therapy: ICS + LABA + LAMA) 2, 3

Note: Patients with ACO have more frequent exacerbations, worse quality of life, and possibly higher mortality compared to COPD or asthma alone; approximately 20% of patients with obstructive airway disease have ACO features 3, 5, 6

Severity Stratification and Risk Assessment

COPD Severity Classification

Severity	FEV1 (% predicted)	Clinical Features
Mild	60-80%	Smoker's cough, little/no breathlessness [1]
Moderate	40-59%	Breathlessness on moderate exertion, cough ± sputum [1]
Severe	<40%	Breathlessness on minimal exertion/rest, wheeze, lung hyperinflation, possible cyanosis/edema [1]

Additional risk factors requiring closer monitoring:

• History of frequent exacerbations (≥2/year) or hospitalizations 1
• Rapid FEV1 decline (>50 mL/year) 3
• Comorbidities: cardiovascular disease, osteoporosis, diabetes, depression 1

Common Diagnostic Pitfalls to Avoid

1. Do not rely on bronchodilator reversibility alone to differentiate COPD from asthma; many COPD patients show modest reversibility, and the test varies day-to-day 1, 3

2. Do not assume cough, sputum, or wheeze reliably distinguish between conditions; these features overlap significantly 4

3. Do not delay spirometry; physical examination alone cannot detect moderate-to-severe airflow obstruction 3

4. Do not prescribe bronchodilators or ICS without objective spirometric confirmation of airflow limitation 3

5. Do not overlook asthma as a risk factor for developing COPD; long-standing asthma can lead to irreversible airflow limitation 1, 7

Follow-Up and Monitoring

At every visit, assess:

• Medication dose, frequency, and inhaler technique 2, 3
• Symptom relief and functional status using standardized questionnaires (mMRC, CAT) 1, 3
• Smoking status and reinforce cessation 1, 3
• Pulse oximetry; SpO2 <88% warrants arterial blood gas and evaluation for long-term oxygen therapy 3

Repeat spirometry:

• Annually to monitor FEV1 decline 3
• After 2 weeks of new therapy to assess objective response 2

Evaluate for pulmonary rehabilitation if exercise capacity is reduced or respiratory muscle function is impaired 2, 3